Publications by authors named "Gido Gravesteijn"

Article Synopsis
  • NOTCH3cys variants are common and linked to various small vessel diseases, including early-onset stroke and dementia, but there is no comprehensive staging system to assess their severity.
  • A cohort study created and validated a simple staging system for NOTCH3-SVD by analyzing data from several international cohorts and the UK Biobank, focusing on the impact of these variants on CVD outcomes and cognition.
  • The new system includes 9 disease stages, aiding in understanding the relationship between stages and clinical outcomes like ischemic strokes, cognitive function, and brain damage.
View Article and Find Full Text PDF

Background And Objectives: Pathogenic variants in are the main cause of hereditary cerebral small vessel disease (SVD). SVD-associated variants have recently been categorized into high risk (HR), moderate risk (MR), or low risk (LR) for developing early-onset severe SVD. The most severe NOTCH3-associated SVD phenotype is also known as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).

View Article and Find Full Text PDF
Article Synopsis
  • A new recessive genetic disorder called NIT1-small vessel disease has been identified, caused by variants in the NIT1 gene that lead to loss of function.* -
  • Researchers analyzed seven patients using various techniques like exome sequencing and MRI, discovering significant brain abnormalities and movement disorders primarily presenting in mid-adulthood.* -
  • The disease is characterized by a specific set of symptoms including dilated perivascular spaces in the basal ganglia and intracerebral hemorrhages, highlighting its unique features among cerebral small vessel diseases.*
View Article and Find Full Text PDF
Article Synopsis
  • Cysteine-altering missense variants in the NOTCH3 protein cause NOTCH3-associated small vessel disease (NOTCH3-SVD), which shows a wide range of severity, including severe conditions like CADASIL and milder cases.
  • The study aimed to enhance risk prediction for NOTCH3-SVD by analyzing differences in NOTCH3cys variant frequencies across various EGFr domains, categorizing them into low, medium, or high-risk classifications.
  • The findings revealed that certain EGFr domains (1-6, 8, 11, and 26) were associated with a significantly higher stroke risk compared to others, indicating the potential for genotype-based risk stratification in clinical settings.
View Article and Find Full Text PDF
Article Synopsis
  • The study addresses the challenges of interpreting Neurofilament Light chain (NfL) levels due to a lack of specific reference values for different ages and diseases.
  • Researchers created an interactive interface that uses NfL data from 1698 individuals (healthy and those with neurological conditions) to help visualize and interpret results.
  • This tool offers clinicians a valuable resource for understanding individual NfL levels, highlighting a flexible approach to interpreting age-related biomarkers in neurology.
View Article and Find Full Text PDF

Background: A retrospective study has shown that EGFr (epidermal growth factor-like repeat) group in the gene is an important cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) disease modifier of age at first stroke and white matter hyperintensity (WMH) volume. No study has yet assessed the effect of other known CADASIL modifiers, that is, cardiovascular risk factors and sex, in the context of EGFr group. In this study, we determined the relative disease-modifying effects of EGFr group, sex and cardiovascular risk factor on disease severity in the first genotype-driven, large prospective CADASIL cohort study, using a comprehensive battery of CADASIL clinical outcomes and neuroimaging markers.

View Article and Find Full Text PDF

Background: To determine whether extremely mild small vessel disease (SVD) phenotypes can occur in variant carriers from Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) pedigrees using clinical, genetic, neuroimaging, and skin biopsy findings.

Methods: Individuals from CADASIL pedigrees fulfilling criteria for extremely mild -associated SVD (mSVD) were selected from the cross-sectional Dutch CADASIL cohort (n=200), enrolled between 2017 and 2020. Brain magnetic resonance imaging were quantitatively assessed for SVD imaging markers.

View Article and Find Full Text PDF

Aims: CADASIL, the most prevalent hereditary cerebral small vessel disease, is caused by cysteine-altering NOTCH3 variants (NOTCH3 ) leading to vascular NOTCH3 protein aggregation. It has recently been shown that variants located in one of NOTCH3 protein epidermal growth-factor like repeat (EGFr) domains 1-6, are associated with a more severe phenotype than variants located in one of the EGFr domains 7-34. The underlying mechanism for this genotype-phenotype correlation is unknown.

View Article and Find Full Text PDF

Objective: To determine the small vessel disease spectrum associated with cysteine-altering variants in community-dwelling individuals by analyzing the clinical and neuroimaging features of UK Biobank participants harboring such variants.

Methods: The exome and genome sequencing datasets of the UK Biobank (n = 50,000) and cohorts of cognitively healthy elderly (n = 751) were queried for cysteine-altering variants. Brain MRIs of individuals harboring such variants were scored according to Standards for Reporting Vascular Changes on Neuroimaging criteria, and clinical information was extracted with ICD-10 codes.

View Article and Find Full Text PDF

CADASIL is a vascular protein aggregation disorder caused by cysteine-altering NOTCH3 variants, leading to mid-adult-onset stroke and dementia. Here, we report individuals with a cysteine-altering NOTCH3 variant that induces exon 9 skipping, mimicking therapeutic NOTCH3 cysteine correction. The index came to our attention after a coincidental finding on a commercial screening MRI, revealing white matter hyperintensities.

View Article and Find Full Text PDF
Article Synopsis
  • CADASIL is a disease linked to NOTCH3 that affects small blood vessels in the brain, characterized by GOM deposits in arteries; however, how these deposits form and affect disease progression is not well understood.
  • Researchers studied GOM deposits in genetically modified mice and human patients, discovering that these deposits are dynamic and grow larger and more complex as the mice age, which led to the creation of a new classification system.
  • Despite similarities in GOM stages between mice and humans, the mutant mice didn't develop the most severe GOM seen in patients, highlighting a lack of severe associated brain damage and cognitive deficits, suggesting the need for further research on GOM's role in CADASIL.
View Article and Find Full Text PDF

Objective: To validate whether serum Neurofilament Light-chain (NfL) levels correlate with disease severity in CADASIL, and to determine whether serum NfL predicts disease progression and survival.

Methods: Fourty-one (pre-) manifest individuals with CADASIL causing mutations and 22 healthy controls were recruited from CADASIL families. At baseline, MRI-lesion load and clinical severity was determined and serum was stored.

View Article and Find Full Text PDF

Objective: To determine the frequency of distinctive EGFr cysteine altering mutations in the 60,706 exomes of the exome aggregation consortium (ExAC) database.

Methods: ExAC was queried for mutations distinctive for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), namely mutations leading to a cysteine amino acid change in one of the 34 EGFr domains of NOTCH3. The genotype-phenotype correlation predicted by the ExAC data was tested in an independent cohort of Dutch CADASIL patients using quantified MRI lesions.

View Article and Find Full Text PDF

Background: Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC).

Methods: Eligible patients had HER2-negative, stage II/III BC.

View Article and Find Full Text PDF